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OBJECTIVES: A healed intestinal mucosa is the aim of therapy in acute ulcerative colitis (UC). Disruption of mucosal
woundhealingmay lead to severe complications including intestinal fibrosis. This studyexaminedmucosal
gene expression in the healing process of acute UC with a special focus on known mediators of fibrosis.
METHODS: Endoscopic biopsies from patients with acute, moderate to severe UC were analyzed with a quantitative
polymerase chain reaction array for 84 genes involved in fibrosis pathways. All patients were treated with
infliximab (anti– tumor necrosis factor). Biopsies were taken before therapy and when disease remission
was reached,definedasaMayoscore of£2,withanendoscopic subscoreof0or1.Ahealthy control group
was included. Immunostaining of matrix metallopeptidase 9 and smooth muscle actin was performed.
RESULTS: Mucosal biopsies from acute UC (n5 28), remission UC (n5 28), and healthy controls (n5 13) were
analyzed. Fibrosis and extracellular matrix-associated genes were upregulated in the endoscopically
healed UC mucosa vs controls, with collagen type III alpha 1 chain, actin alpha 2, lysyl oxidase, TIMP
metallopeptidase inhibitor 3, and caveolin 1 uniquely showing no overlap with acute disease. Pro- and
antifibrotic mediators (interleukin [IL]13 receptor subunit alpha 2, IL1B, IL10, tumor necrosis factor,
snail family transcriptional repressor 1, and C-C motif chemokine ligand 2) were upregulated in both
acute and healed UC compared with controls. An attenuated pattern of the canonical transforming
growth factor beta (TGFB) pathway was observed in acute UC and to a lesser extent in the healed
mucosa, except for TGFB2, which was enhanced.
DISCUSSION: The endoscopically healed mucosa of UC showed a persisting dysregulation of fibrosis-associated
mediators compared with controls, including extracellular matrix remodeling, profibrotic cytokines,
and TGFB signaling pathways.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A103
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INTRODUCTION
Ulcerative colitis (UC) is a chronic, relapsing inflammatory
disease affecting the colon (1). The pathogenesis is complex
involving dysregulated immune responses to mucosal injury,
with persistent inflammation and disruption of wound healing
(2,3). The proinflammatory cytokine tumor necrosis factor
(TNF) plays a pivotal role in mediating inflammation in UC.
Antibodies targeting TNF induce mucosal healing in over 60%
of patients with inflammatory bowel disease (IBD) (4,5).
Achieving mucosal healing is the current goal of treatment in
IBD as associated with clinical improvement and longer relapse-
free periods (6).
There is an increasing need for knowledge of which mediators
are involved inmucosal healing. This is emphasized by the fact that
10%–30% of patients with IBD are unresponsive to anti-TNF
therapy, as well the lack of therapies targeting intestinal fibrosis in
IBD (7,8). Intestinal fibrosis is a severe complication in IBD,
causing excessive scar tissue formation in the bowel wall, with
distortion of tissue architecture and intestinal function as sequelae
(9,10). InUC, up to 11% experience fibrostenotic complications, vs
over 50% in Crohn’s disease (9). Recent studies suggested that the
complications of intestinal fibrosismay be severely underestimated
in UC, indicating that fibrosis is more prominent in the patho-
genesis of UC than previously attributed (11,12).
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Following injury to the intestinal barrier, the body is dependent
on executing a swift and effective response to prevent pathogen
invasion (13). This is a complex process involving hemostasis,
followed by fibrogenesis, epithelial regeneration, scar tissue
remodeling, and eventually restoration of the intestinal barrier
(13,14). Mesenchymal cell activation by transforming growth
factor beta (TGFB) is central for production of extracellular matrix
(ECM) proteins and wound contraction (ECM) (15). Degradation
and turnover of the ECM is tightly regulated by matrix metal-
lopeptidases (MMPs) and their inhibitors (TIMPs) (16). The ca-
nonical TGFB pathway is central in fibrosis progression and
implicated in IBD (17,18). TGFB binds to the membrane-bound
TGFB receptors, which activate intracellular SMAD signaling
cascades. Mediators of the TGFB–SMAD pathway are therefore of
interest as target for antifibrotic therapy (19–21).
Currently, no methods exist for detecting early stages of in-
testinal fibrosis (9,10). In this study, we applied a PCR array of
fibrosis-associated mediators in a well-stratified cohort of patients
with acute UC that have been treated with anti-TNF until disease
remission. The differential expression of fibrosis-associated
mediators in the healed mucosa of UC may give insights into ac-
tive pathways and potential therapeutic targets for fibrosis.
MATERIALS AND METHODS
Ethical considerations
The study and storage of biological samples was approved by the
Regional Committee for Medical and Health Research Ethics
North (Reference no: REK1349/2012) and performed in accor-
dance with the Declaration of Helsinki principles. Written and
informed consent was obtained from all study participants.
Patient population
Patients were included from the IBD Biobank at the University
Hospital of North Norway; the IBD cohort has previously been
described (22). Patients aged 18 years or older, with moderate to
severe UC defined as Mayo score $6, were included. All patients
had been treated with an induction course of infliximab 5 mg/kg
intravenously at 0, 2, and6weeks followedbymaintenance therapy
every 4–8weeks.Onlypatientswhoachieved endoscopic remission
after infliximab therapy were included. We defined endoscopic
remission as aMayo score#2with no individual subscore.1 (23).
Geboes score was assessed on available hematoxylin and eosin-
stained slides at endoscopic remission by an experienced pathol-
ogist (S.W.S.), with histological remission defined as Geboes score
,3.1 (24). Primary sclerosing cholangitis, pregnancy, lactation,
and a history of cancer were exclusion criteria.
Tissue samples
Endoscopic biopsies were obtained from the most inflamed re-
gion of colonic mucosa before infliximab therapy and a new bi-
opsy obtained from the same region at the time point of disease
remission. Biopsies were taken with standard endoscopic forceps
and immediately immersed inRNA later (AmbionAustin, TX) or
10% formalin for quantitative polymerase chain reaction (qPCR)
or histological analysis, respectively. RNAwas extracted using the
Promega method (Promega Madison, WI) following manu-
factures’ instructions and stored at270 °C.
Control group
A healthy control group referred for colonoscopy was included if
the following criteria were met: age 18 years or above, a complete
colonoscopy examination with normal macroscopic and histo-
logical findings, and no diarrhea in the presenting history.
Pregnancy or lactation, previous or current cancer, systemic in-
flammatory disease, and presence or a history of colonic polyps
were exclusion criteria. Endoscopic biopsies were taken from the
sigmoid or rectal mucosa.
qPCR analysis
RNA concentration was determined with Nanodrop (Thermo
Fisher Scientific, Waltham, MA). Reverse transcriptase was per-
formed with Quantitect 2 step Kit (Qiagen, Hilden, Germany).
The RT2 profiler PCR Array Human Fibrosis PAHS-120Z
(product nr 330213 Qiagen, Hilden, Germany) was used
according to the manufacturer’s instructions with RT2SYBER
Green mastermix (Qiagen, Hilden, Germany). Real-time qPCR
was performed with Bio-Rad CFX96 (Roche Diagnostics, Rotk-
reuz, Switzerland). A computed tomography (CT) cutoff for
lower limit of detection was set at 40 (see Supplementary In-
formation, Supplementary Digital Content 1, http://links.lww.
com/CTG/A103).
Immunostaining
Four-μm sections of formalin-fixed paraffin-embedded samples
were deparaffinized and rehydrated through a series of xylene to
alcohol. DAKO antigen retrieval buffer (pH6) (DAKO, Glostrup
Denmark) was used in a waterbath for 20minutes at 100 °C and 20
minutes of cooling at room temperature. Sections were blocked
with10%goat serum.Primaryantibodieswere incubatedovernight
at 4 °C. Secondary goat antibodies conjugated with Alexa 555 (Cell
Signaling Technologies, Danvers, MA) or Alexa 647 (Invitrogen,
Thermo Scientific, Waltham, MA) were incubated for 90 minutes
at room temperature, and cell nuclei stained with Hoechst 33258.
Negative isotype- and concentration-matched controls were used
(antibody details listed in Supplementary Table 1, see Supple-
mentary Digital Content 1, http://links.lww.com/CTG/A103).
Images were obtained with a Zeiss LSM780 CLSM microscope
(Carl Zeiss Microscopy, Zena, Germany) using Zen 2012 black
edition software. Three nonoverlapping, representative images at
3200magnification were used for quantification with Volocity 6.3
software (PerkinElmer Waltham, MA) with positive fluorescence
area givenas a ratioover total nuclei area for each slide. Imageswere
processed inAdobePhotoshopCC 2019 (Adobe Systems Software,
Ireland Ltd,Dublin, Ireland), and adjustments to image histograms
were applied to whole image only. The Human Protein Atlas da-
tabase (www.proteinatlas.org) was used to identify validated anti-
body staining with a high reliability score (“enhanced score”).
Statistics
Data were analyzed using R Statistical Environment (https://www.
r-project.org) with Bioconductor R software for principal com-
ponent analysis and impute package for missing values. Norm-
finder (https://moma.dk/normfinder-software) software was used
for evaluating reference genes used for normalization (25).
For comparative gene analysis, we used the linear modeling
framework from theR Stats Packagewith the (lm() function using
normalized CT values (delta CT). Independent samples and
paired samples were taken into account. Correction for sex and
endoscopic remission status was performed. P values were ad-
justed formultiple testing using the BenjaminiHochbergmethod,
with a significant adjusted P , 0.05 set as threshold (26). Com-
parison of gene expression between groups was given as log2 fold



















change. Quantification of immunostaining was performed with t
tests for independent groups and a paired t test when comparing
acute and remission disease, all after control of normality with
IBM SPSS Statistics version 25.0 (Armonk, NY). Plot and bar
charts were visualized with GraphPad prism v. 7 (La, Jolla, CA).
RESULTS
Patient population
Twenty-eight patients with moderate to severe acute UC and 13
healthy controls met the study inclusion criteria. Five patients
with UC were newly diagnosed, whereas the majority had well-
established disease. Patient demographics are shown in Table 1.
At endoscopic remission, 16 patients had a Mayo endoscopic
subscore of 0. For endoscopic remission, histology was available
for n 5 7 patients with UC, of these, n 5 6 were in histological
remission (Geboes score ,3.1) (See Supplementary Table 2,
Supplementary Digital Content 1, http://links.lww.com/CTG/
A103). Biopsies fromall healthy controls (n5 13) showednormal
histological findings, with no inflammation.
Unique expression pattern in the healed mucosa of UC
All samples passed qPCR quality control, and interleukin 5 (IL5)
was excluded because of .25% of CT values over 40 and not
included in further analyses. Principal component analysis showed
separation of acuteUC, remissionUC, and healthy control samples
in the first principal component, with 44.5% of the variance
explained (Figure 1a). Gene expression analysis revealed a signifi-
cant number of differently expressed genes in all sample groups
with a total of 41 upregulated and 38downregulated genes.AVenn
diagram (Figure 1b) depicts the overlap of differentially expressed
genes between the comparisons of groups with active UC (A),
remission (R), and control samples (N).Wenoted that 6 geneswere
uniquely expressed in the endoscopically healed mucosa of UC vs
controls (differentially expressed compared with control samples
with no overlap to active UC). These genes actin alpha 2, smooth
muscle (ACTA2), caveolin 1 (CAV-1), collagen type III alpha 1
chain (COL3A1), lysyl oxidase (LOX), andTIMPmetallopeptidase
inhibitor 3 (TIMP3), were all upregulated compared with healthy
controls, whereas integrin subunit beta 6 (ITGB6)was significantly
downregulated. The latter 4 genes (COL3A1, LOX, TIMP3, and
ITGB6) are associatedwith theECMremodeling.Angiotensinogen
(AGT) was the only gene with an expression pattern showing
upregulation in acute disease and downregulation in healed mu-
cosa compared with controls. The entire gene expression pattern is
shown in Figure 2a. Gene table and pathway annotations are given
in Supplementary Table 3 and Supplementary Figure 1 (see Sup-
plementary Digital Content 1, http://links.lww.com/CTG/A103).
Attenuation of the TGFB canonical pathway in UC
The profibrotic TGFB-SMAD pathway (illustrated in Figure 3)
showed a significant dysregulated signaling pattern in acute UC
and to a lesser extent in endoscopic remission (Figure 2b).
Table 1. Clinical characteristics at study inclusion time for patients with acute UC and control group
UC (n5 28) Controls n 5 13 P-valuea
Sex, male/female (n) 18/10 7/6 0.73
Age at diagnosis (median, [range]) 51 (18–69) 39 (20–82) 0.05
Smoking status (n) non-/ex-/current smoker 16/1/11 — NA
Disease duration mo (median, [range]) 52.5 (0–372) — NA
Disease extent (n)
Proctitis 6 — NA
Left sided 15 — NA
Extensive 7 — NA
Biopsy location endoscopy (n) (rectum/
sigmoid)
13/15 5/8 0.5
Mayo score baseline 10 (7–12) — NA
Endoscopic subscore 3 (1–3)c — NA
Medication at baselineb
5-ASA 19 0 NA
Steroids po/iv 12/0 0 NA
AZA or MTX 11 0 NA
Anti-TNF 0 0 NA
Variables are given asmedian with range, if not otherwise indicated. No significant differences (P, 0.05) were found between the UC and the control group with regard to
age, sex, or biopsy location (independent samples t test and Fisher exact test for continuous and categorical variables were used, respectively). Disease extent was defined
using the Montreal Classification as recommended by ECCO guidelines (6). Patient medication at baseline included no anti-TNF therapy within the last 3 months.
5-ASA, 5-aminosalicylate; AZA, azathioprine; MTX, methotrexate; NA, not applicable; TNF, tumor necrosis factor; UC, ulcerative colitis.
aComparison between UC and healthy controls.
bPatients can be on >1 medication at baseline.
cTwopatients had an endoscopic subscore of 1, howevermet the inclusion criteria as a fullMayo scorewas>6, bothwith high rectal bleeding scores andhistologically active
disease with cryptitis and crypt abscesses.


















Fibrosis Mediators in the Colonic Mucosa 3
Comparison of acute UC and healthy controls revealed an upre-
gulation of TGFB2 and TGFB3, but not TGFB1. Furthermore, the
corresponding receptors for these ligands, TGFB receptor 1
(TGFBR1) and TGFB receptor 2 (TGFB2), were downregulated
along with intracellular SMAD signaling mediators SMAD2,
SMAD3, SMAD4, SMAD6, and SMAD7. Inhibitors of the
Figure 1.Principal component plot and Venn diagrams. (a) PCAwith separation of groups seen along the x-axis. Of note, 44.5%of the variance is explained
by PCA1. (b) Venn diagrams showing overlap of significantly expressed genes (adjusted P , 0.05) between groups: acute UC vs healthy control group
(AvN), remission UC vs healthy control group (RvN), and acute UC vs remission UC (AvR). PCA, principal component analysis; UC, ulcerative colitis.



















Figure 2. Gene expression analysis. (a) Heatmap of all genes examined in the PCR array with an unsupervised cluster analysis, with study groups and sex
given. (b) Pathway analysis was performed using gene annotations provided by RT2 Profiler Human Fibrosis array (Qiagen). Selected bar charts show log2
fold changes with SE given for significantly differentially expressed genes (adj. P , 0.05). Group comparisons are given as follows: acute UC vs healthy
control group (AvsN) and remission UC vs healthy control group (RvsN).UC, ulcerative colitis.


















Fibrosis Mediators in the Colonic Mucosa 5
TGFB-SMADpathway, THBS2 andBMP7, were increased in both
the acute and endoscopically healed UC mucosa. Furthermore,
TGFB3 normalized, whereas a persistent overexpression of TGFB2
was observed at the time of endoscopic remission.
Other relevant fibrotic mediators in UC
ECM remodeling enzymes MMP3 and MMP1 showed the most
prominent log2 fold changes in acute and healed UC compared
with controls. Proinflammatory cytokines and chemokines were
strongly upregulated during acute disease, including IL 1 beta
(IL1B), interferon gamma (IFNG), and TNF (Figure 2b). Com-
parison of the healed UC mucosa with the healthy control group
revealed profibrotic genes IL 13 receptor subunit alpha 2
(IL13RA2) and Gremlin-1 (GREM 1) among the top overex-
pressed genes. Several upregulated inflammatory mediators
normalized completely in the healed mucosa including MMP9,
IFNG, IL 1alpha (IL1A), and C-C motif chemokine ligand 3
(CCL3). Immunostaining was consistent with the gene expres-
sion pattern of MMP9 (shown in Figure 4). In contrast, several
fibrosis mediators showed little or no change in gene expression
following anti-TNF therapy (BMP7, GREM1, CCL2, and
CXCR4). In this cohort, TNF was still found to be upregulated in
the mucosa following anti-TNF therapy. Comparison of
endoscopic subscore 0 and 1 in disease remission revealed sig-
nificant differences in 12 genes with log2 fold changes ,1. Of
these genes, IL10 and MMP14 were upregulated, whereas the
remaining genes were downregulated (integrin subunit alpha 1
(ITGA1), integrin subunit beta 1 (ITGB1), integrin subunit beta 6
(ITGB6), SMAD4, signaling transducer and activator of tran-
scription 6 (STAT6), epidermal growth factor, specificity protein
1 (SP1), and latent transforming growth factor–binding protein 1
(LTBP1). The remaining genes (n 5 31) were not affected by
endoscopic remission score 0 or 1. Correction for sex revealed
only CCL3 to show a significant sex difference (log2 fold change
male vs female: 20, 15).
DISCUSSION
We have clearly demonstrated that genes involved in ECM
remodeling and fibrosis development do not all normalize in
the endoscopically healed mucosa of UC (defined as Mayo
endoscopic subscore of 0 or 1). Over half of the investigated
fibrosis-associated genes were differentially expressed in the
healed UC mucosa. This supports the notion that fibrosis is
indeed an important component in the pathophysiology of UC.
We found an increased TGFB2 and TGFB3 ratio in acute
UC, with TGFB3 expression not normalizing in endoscopic
Figure 3. TGFB signaling in the colonicmucosa. Following injury to the epithelial barrier, activity of matrix metallopeptidases (MMPs) is increased. TGFB is
bound in a latent form in the extracellularmatrix.MMPs degrade the collagenmatrix, also releasing and activating TGFB (19). The canonical TGFBpathway
involves activation of membrane-bound TGFB receptors 1 and 2, which phosphorylates SMAD 2/3 and together with SMAD4 before translocating to the
nucleus (21). TGFB promotes recruitment and differentiation of fibroblasts into myofibroblasts, increasing production of collagen and TIMPs. Caveolin 1,
a glycoprotein in the cell membrane, inhibits this signaling by internalizing the TGFB receptors (36). TIMP, tissue inhibitor of metallopeptidase.



















Figure4. Immunostaining ofMMP9andACTA2. Antibodiesdirected atMMP9andACTA2had the highest upregulated anddownregulated genepatterns in
our study with enhanced antibody scores. Panels show representative immunostaining of formalin-fixed, paraffin-embedded colonic endoscopic biopsies
from acute UC, remission UC, and a healthy control group at 3400 magnification. Scale bars 5 35 μm. Dual staining with monoclonal rabbit antibody
against MMP9 ([1/400], Cell Signaling Technologies) and monoclonal mouse antibody against ACTA2/SMA (DAKO, [0.35 μg/mL]) were used. Cell nuclei
are stainedwithHoechst (blue). Positive cytosolic staining of stromal cells was observed forMMP9 (green), whereas amembranous/cytoplasmic signal was
seen in ACTA2-positive cells (red). A significant decrease (P, 0.05) of MMP9was seen comparing acuteUCwith remissionUC or normal controls, but not
for ACTA2. Further antibody details are given in Supplemental Table 1(see Supplementary Digital Content, http://links.lww.com/CTG/A103). A negative
control is shown in the white frame for acute UC (bottom left panel). ACTA2, actin alpha 2; UC, ulcerative colitis.


















Fibrosis Mediators in the Colonic Mucosa 7
remission. In contrast, the well-known profibrotic TGFB1 was
present, but not significantly expressed in the UC mucosa. We
believe that the balance of TGFB isoforms in different UC disease
phases may be important for achieving mucosal healing and a po-
tential factor to modulate. Indeed, others have reported differences
in the TGFB ratio between patients withUCwho respond or not to
anti-TNF therapy (27). Furthermore, intestinal myofibroblasts
isolated from healthy controls and patients with IBD have been
shown to secrete different TGFB isoform ratios (28). All 3 TGFB
isoforms are present in the intestine; however, their role in UC is
unclear (19,21). Looking to other organ systems, TGFB1 and
TGFB2 have been found to promote ECM deposition during skin
wound healing, whereas TGFB3 reduces scarring (19,29). In sum,
knowledge of the TFB isoforms role in UC is incomplete, war-
ranting further research.
Although we found an upregulation of the TGFB2 and TGFB3,
the canonical TGFB pathway showed an attenuated response with
downregulated TGFB receptors (TGFBR1 and TGFBR2), together
with intercellular SMAD signaling mediators. This might be an
appropriate response in the acute phase of inflammation, as TGFB
is recognized to be released from its latent bound form in the ECM
by MMPs and other ECM–degrading factors (19). Indirectly, our
findings support this with overexpression of MMPs and extracel-
lular remodeling enzymes in acuteUC, suggesting an abundance of
released and activated TGFB. However, the canonical TGF path-
way does not normalize in the endoscopically healed UC mucosa,
suggestive of a persistent dysregulation.
As expected, proinflammatory genes showed a pattern of re-
duction, and even normalization following anti-TNF therapy in
agreementwithother studies (27,30–33). In contrast, severalfibrosis
mediators showed little or no change in gene expression following
anti-TNF therapy including BMP7, GREM1, CCL2, and CXCR4.
Specific to the endoscopically healed mucosa, a set of genes asso-
ciated with collagen synthesis and degradation (ACTA2, COL3A1,
LOX, and TIMP3) were upregulated compared with controls. In
summary, our findings show that fibrosis-associated mediators are
still dysregulated in the endoscopically healed UC mucosa com-
pared with healthy controls. This is in keeping with other reports
that the healed UC mucosa remains dysregulated (27,32). A recent
study byArijs et al. found a large overlap ofmucosal genes that were
persistently dysregulated in patients with UC responding to inflix-
imab (anti-TNF) or vedolizumab (anti-a4bb7 integrin), suggesting
that unidentified pathways are yet to be targeted (34). Furthermore,
vedolizumab was found to influence a unique set of mucosal genes
independent of anti-TNF therapy. It is exceedingly interesting
whether the new biological therapies, including vedolizumab and
ustekinumab (inhibitor of p40 subunit of IL12 and IL23), will target
additional pathways and influence fibrosis. Our findings highlight
the current knowledge gap of fibrosis-associated pathways in UC,
also evident in the clinics as no effective antifibrotic therapies exist.
Our finding of an upregulated CAV-1 in the healed UC mu-
cosa may reflect a fibroprotective mechanism, as reported in
murine studies (35). The protein Cav-1 acts as the scaffolding in
caveolae of the cell membrane, important for endocytosis and cell
signaling (36). However, to our knowledge, the role of CAV-1 in
IBD is little explored. One study supports the location of CAV-1
and -2 expression in the colonic mucosa (37). Interestingly, the
literature reports CAV-1 to exhibit antifibrotic properties by
binding and internalizing TGFB receptors on the cell membrane,
effectively attenuating TGFB signaling and reducing collagen
production (38). A low gene expression of CAV-1 has been
reported in other fibrotic disorders including idiopathic pulmo-
nary fibrosis and scleroderma (38). In addition, we found an
interesting gene expression pattern forAGT, being upregulated in
acute disease and downregulated in the healed UC mucosa.
Mediators of the renin-angiotensin-aldosterone system are found
in many tissues including the colon (39). Inhibitors of the renin-
angiotensin-aldosterone system are well-established therapies for
prevention of end-organ damage in cardiac and renal disease, and
also of interest in IBD as therapeutic targets for inflammation and
fibrosis.
IL13RA2 was among the top DEGs in our study. Interestingly,
highmucosal expression of this receptor in IBDhas been linked to
anti-TNF unresponsiveness and impaired restoration of the in-
testinal barrier in a murine Dextran sulfate sodium colitis model
(40). Both profibrotic and antifibrotic properties have been de-
scribed in mouse models of colitis and pulmonary fibrosis, re-
spectively; thus, tissue and cellular context is important (41,42).
Taken together, IL13RA2 is emerging as an interesting future
target both for refractory UC and in modulating fibrosis.
A limitation to the study is the lack of a general consensus on
what constitutes a “truly healed”mucosa. The widely used Mayo
score includes endoscopic subgrades 0 and 1 in disease remission,
with a score of 1 allowing for the presence of mild erythema,
decreased vascular pattern, and mild friability. The definitions of
mucosal healing are currently being debated, with endoscopic
subscore 0 and histological remission being associated with im-
proved clinical outcomes (43). However, histological remission
does not necessary imply endoscopic remission and vice versa. In
a recent study, Magro et al. (44) showed that histological indexes
could be associated with endoscopic outcomes with a high sen-
sitivity when the Mayo endoscopic subscore was set at 1. Of the 7
patients in our study with available histological assessment, 1
patient met the criteria for histological remission with an endo-
scopic subscore of 1. This raises the questions of how do we
distinguish between transcription patterns of inflammation, tis-
sue restitution, and those representing the underlying disease?
Some overlap is likely. Is the UC mucosa ever truly inactive?
Arguably, we could have used stricter remission criteria; on the
other hand, most genes did not show any significant difference
when corrected for endoscopic score of 0 and 1 in disease re-
mission. Although the paired samples design is a strength re-
ducing interpatient variation, our sample size was limited by
available biopsies in the IBD Biobank and at risk of type II error.
Another limitation is the use of a preselected gene panels asso-
ciated with general human fibrosis, thus not comprehensive. The
heterogeneity of cell populations across biopsies is also important
to take into account when interpreting results (45).
Apart from CCL3, we did not uncover any sex-dimorphic pat-
terns for our gene set. In our study,most patients withUChadwell-
established UC; however, the role of disease duration on fibrosis
development is not clear. A large histopathology study of fibrosis in
UC found that the degree of fibrosis was linked to the severity ad
chronicity of disease and, interestingly, not to disease duration (46).
Thus, intestinal fibrosis is also a complication occurring in short-
standingUC.Althoughdifferent disease entities,we andothers have
previously found that themucosal gene expression of inflammatory
cytokines between UC and Crohn’s disease is remarkably similar
(47,48). In view of this, our findings could be relevant for future
research in Crohn’s disease; however, this remains to be explored.
Comparison ofmucosalfibrosismediators in patientswithUCwith
established fibrotic disease was not within the scope of the present



















study, but of interest for future work. Combining knowledge of
mucosal fibrosis mediators between anti-TNF responders and
nonresponders may be useful as therapeutic biomarkers, providing
clinicians with tools to personalize therapy.
In conclusion, we have seen a significant modulation of genes
associated with both inflammation and fibrosis in patients treated
to a clinical and endoscopically verified healed mucosa. The
mucosa of UC in disease remission showed a persistent dysre-
gulation of fibrosis-associated genes, with an attenuated pattern
of TGFB signalingmediators inUC.We identifiedmucosal TGFB
isoforms, CAV-1 and AGT as potential antifibrotic targets in UC,
of interest for future research.
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Study Highlights
WHAT IS KNOWN
3 Intestinal fibrosis is a severe complication in IBD.
3 No effective antifibrotic therapies exist for intestinal fibrosis.
3 Recent studies report that intestinal fibrosis is
underestimated in UC.
WHAT IS NEW HERE
3 Profibrotic mediators are dysregulated in the endoscopically
healed mucosa of UC, including transforming growth factor
beta 2 (TGFB2).
3 Genes involved in ECM remodeling were uniquely
upregulated in the endoscopically healed mucosa of UC
compared with healthy controls.
TRANSLATIONAL IMPACT
3 Identification of mucosal markers warranting further
exploration as potential antifibrotic targets in UC therapy.
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